Emerging oral drugs for relapsing-remitting multiple sclerosis.
about
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyGlycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic propertiesInfection risk in patients on multiple sclerosis therapeutics.Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.Current and future therapies for multiple sclerosis.
P2860
Emerging oral drugs for relapsing-remitting multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@en
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@nl
type
label
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@en
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@nl
prefLabel
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@en
Emerging oral drugs for relapsing-remitting multiple sclerosis.
@nl
P2860
P921
P1476
Emerging oral drugs for relapsing-remitting multiple sclerosis
@en
P2093
Claudio Gasperini
Serena Ruggieri
P2860
P304
P356
10.1517/14728214.2011.642861
P407
P577
2011-12-07T00:00:00Z